| Literature DB >> 28128956 |
Marco Pieroni, Elisa Azzali, Nicoletta Basilico1, Silvia Parapini2, Michal Zolkiewski3, Claudia Beato, Giannamaria Annunziato, Agostino Bruno, Federica Vacondio, Gabriele Costantino4.
Abstract
Malaria eradication is a global health priority, but current therapies are not always suitable for providing a radical cure. Artemisinin has paved the way for the current malaria treatment, the so-called Artemisinin-based Combination Therapy (ACT). However, with the detection of resistance to ACT, innovative compounds active against multiple parasite species and at multiple life stages are needed. GlaxoSmithKline has recently disclosed the results of a phenotypic screening of an internal library, publishing a collection of 400 antimalarial chemotypes, termed the "Malaria Box". After analysis of the data set, we have carried out a medicinal chemistry campaign in order to define the structure-activity relationships for one of the released compounds, which embodies a benzothiophene-2-carboxamide core. Thirty-five compounds were prepared, and a description of the structural features responsible for the in vitro activity against different strains of P. falciparum, the toxicity, and the metabolic stability is herein reported.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28128956 DOI: 10.1021/acs.jmedchem.6b01685
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446